leadf
logo-loader
viewKintara Therapeutics
(
NASDAQ:KTRA
)

Kintara Therapeutics activates its Phase 2/3 clinical trial to treat GBM in 15 US sites

Kintara Therapeutics, Inc. (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive the group's Phase 2/3 clinical trial to treat glioblastoma multiforme has been activated in 15 US sites as of May 14, 2021.

Zarrabian says the design trial and execution is 'critical' and he's pleased with the progress the trial has made thus far. GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM.

Quick facts: Kintara Therapeutics

Follow
NASDAQ:KTRA

Price: 0.88 USD

Market Cap: $28.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Kintara Therapeutics enrolls patients at 26 sites within around 7 months

Kintara Therapeutics (NASDAQ:KTRA) Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive its VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has now been activated in 26 US sites. Zarrabian...

2 weeks, 3 days ago

2 min read